HT Vista Ltd has launched a new diagnostic function on the HT Vista screening device. The new technology enhances its unique, AI algorithm-based cancer screening tool with a diagnostic ability in cases where the specificity exceeds 90 percent. The update went live on March 11 2025, with a new scoring system of low, moderate or high cancer risk which replaces the original numerical HDI scores. This new presentation simplifies interpretation for clinicians, making the screening process easier to communicate with pet owners. HT Vista will be presenting the updated technology at BSAVA Congress, 2025 at stand C42.
Built on validated global data and utilising ever-improving algorithms, HT Vista can now categorise cancer risk levels, based on malignant probability, with a sensitivity of 90 percent and a negative predictive value (NPV) of 98 percent. This translates to a “low cancer risk” result having a malignant probability of 10 percent or less, allowing veterinary teams to rule out cancer of lumps and bumps without the need for invasive procedures. Furthermore, the tool can now provide alerts for some of the low-risk cases, identifying them as lipomas, sebaceus adenomas or benign epithelial masses.
Liron Levy-Hirsch DVM MRCVS, managing director at HT Vista, says, “I am incredibly excited to enhance our already powerful HT Vista screening tool with a new diagnostic capability, providing veterinary teams with an even more comprehensive decision-support system. Our screening technology has already been a game-changer in early detection, and now, with the ability to flag specific tumour types, we are taking another significant step forward. This advancement empowers veterinary professionals to make even more informed decisions, supports shared decision-making with pet owners, and ultimately improves patient outcomes. By reducing the time from suspicion to diagnosis and treatment, we can detect cancer earlier, avoid the ‘wait and see’ approach, and help save more lives.”
On the other end of the scale, a “high cancer risk” result has a malignant probability of 50 percent or more and indicates a stronger likelihood of malignancy. These cases require additional diagnostic tests for mass identification. Additionally, for some of the high-risk cases HT Vista can identify specific malignant masses like mast cell tumours. A “moderate cancer risk”, with malignant probability of 10 to 50 percent, suggests further investigation is recommended, and advises against monitoring over time.
The new update further strengthens HT Vista’s position in bridging the gap between screening and diagnosis. It removes the need for the “wait and see” approach, with a quick and painless procedure that appeals to pet owners. A key distinction from other screening modalities is that it can be nurse-led. In a time of economic tightening the HT Vista is an efficient, cost-effective path to a diagnosis.
Dr Anish Patel, veterinarian and practice owner of Max and Min Veterinary Practice, who has the device installed, commented, “I’m incredibly excited about the updated HT Vista software! The ability to now reach a diagnosis in a non-invasive way is a game-changer, and I can’t wait to see the positive impact it will continue to have on our practice and our patients!”
Delegates attending BSAVA Congress from the 20 to the 22 of March 2025, will have the opportunity to see HT Vista’s enhanced capabilities firsthand at stand C42. Live demonstrations will showcase how the updated tool provides faster, clearer cancer risk assessments. Experts from the HT Vista team will also be on hand to discuss the technology and demonstrate how this advancement can be seamlessly integrated into veterinary practices to support early detection and better patient outcomes. More information on HT Vista’s new screening and diagnostic capabilities can be found here.
